Published in Vaccine Weekly, June 17th, 1996
These findings validate current U.S. Centers for Disease Control and Prevention (CDC) recommendations that people with HIV infection should receive the 23-valent pneumococcal polysaccharide (PPS) vaccine (Pnu-Imune; Lederle, West Henrietta, New York).
Maria C. Rodriguez-Barradas of the VA Medical center, Houston, Texas, and colleagues, studied the response to PPS vaccine in 104 patients with HIV infection treated at their facility.
They reported their findings in the Journal of Infectious...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.